These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 31907646)

  • 1. Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival.
    Ota Y; Takahari D; Suzuki T; Osumi H; Nakayama I; Oki A; Wakatsuki T; Ichimura T; Ogura M; Shinozaki E; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2020 Feb; 85(2):265-272. PubMed ID: 31907646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
    Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
    Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the Neutrophil-to-Lymphocyte Ratio on the Survival of Patients with Gastric Cancer Treated with Nivolumab Monotherapy.
    Yamada T; Hayashi T; Inokuchi Y; Hayashi K; Watanabe H; Komori K; Kano K; Shimoda Y; Fujikawa H; Shiozawa M; Morinaga S; Rino Y; Masuda M; Ogata T; Oshima T
    Target Oncol; 2020 Jun; 15(3):317-325. PubMed ID: 32319020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases.
    Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Takamura H; Ueda N; Kosaka T
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2955-2960. PubMed ID: 33112554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
    Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
    PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
    Grenader T; Waddell T; Peckitt C; Oates J; Starling N; Cunningham D; Bridgewater J
    Ann Oncol; 2016 Apr; 27(4):687-92. PubMed ID: 26787231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximum Efficacy of Immune Checkpoint Inhibitors Occurs in Esophageal Cancer Patients With a Low Neutrophil-to-Lymphocyte Ratio and Good Performance Status Prior to Treatment.
    Hirasawa Y; Kubota Y; Mura E; Suzuki R; Tsurui T; Iriguchi N; Ishiguro T; Ohkuma R; Shimokawa M; Ariizumi H; Horiike A; Wada S; Ariyoshi T; Goto S; Otsuka K; Murakami M; Kiuchi Y; Yoshimura K; Hoffman RM; Tsunoda T
    Anticancer Res; 2024 Aug; 44(8):3397-3407. PubMed ID: 39060084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
    Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
    Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neutrophil-Lymphocyte Ratio as a Prognostic Indicator in Patients Treated with Nivolumab for Gastric Cancer].
    Fujita K; Haruki N; Kurehara H; Ochi N; Yamakawa Y; Harata S; Tsumoto C; Tsuji T; Ito T; Izumi A; Usui R; Shinoda N
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):923-926. PubMed ID: 32541169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer.
    Namikawa T; Yokota K; Tanioka N; Fukudome I; Iwabu J; Munekage M; Uemura S; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Surg Today; 2020 Nov; 50(11):1486-1495. PubMed ID: 32542414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
    Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
    Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
    Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H
    BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers.
    Li M; Spakowicz D; Burkart J; Patel S; Husain M; He K; Bertino EM; Shields PG; Carbone DP; Verschraegen CF; Presley CJ; Otterson GA; Kendra K; Owen DH
    J Cancer Res Clin Oncol; 2019 Oct; 145(10):2541-2546. PubMed ID: 31367835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Lee S; Oh SY; Kim SH; Lee JH; Kim MC; Kim KH; Kim HJ
    BMC Cancer; 2013 Jul; 13():350. PubMed ID: 23876227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
    Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
    Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.